Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea

Journey Medical Corp

2024-Q3 EPS reported -$0.80 revenue$42,514,000

FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.
Net product revenues $14.6M, down 4% YoY; Qbrexza sales up 29% to $7.6M.
Net loss $2.4M ($0.12/sh) vs net income $16.8M ($0.91/sh) in Q3 2023 (included $19M license payment).
Adjusted EBITDA $0.3M ($0.01/sh) vs $20.8M ($1.13/sh) in Q3 2023.
Gross margin improved to 63.9% from 57.9% due to lower inventory charges and royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.